Radius Health, Inc. (NASDAQ:RDUS) VP Brent Hatzis-Schoch purchased 1,778 shares of Radius Health stock in a transaction on Friday, November 10th. The stock was bought at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the transaction, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Radius Health, Inc. (NASDAQ RDUS) opened at $27.71 on Tuesday. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health, Inc. has a 12-month low of $27.16 and a 12-month high of $55.97.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the previous year, the business earned ($1.07) earnings per share. research analysts predict that Radius Health, Inc. will post -5.4 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Radius Health, Inc. (RDUS) VP Brent Hatzis-Schoch Purchases 1,778 Shares of Stock” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/14/radius-health-inc-rdus-vp-brent-hatzis-schoch-purchases-1778-shares-of-stock.html.

A number of equities research analysts have issued reports on RDUS shares. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research report on Friday, November 3rd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $45.00 price target on shares of Radius Health in a research report on Friday, October 6th. Finally, Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $51.00.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. raised its position in shares of Radius Health by 28.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 180,901 shares of the biopharmaceutical company’s stock worth $6,974,000 after acquiring an additional 40,006 shares in the last quarter. American International Group Inc. raised its position in shares of Radius Health by 8.1% during the 3rd quarter. American International Group Inc. now owns 24,949 shares of the biopharmaceutical company’s stock worth $962,000 after acquiring an additional 1,866 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Radius Health by 184.6% during the third quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after buying an additional 1,044,615 shares during the period. ING Groep NV acquired a new position in Radius Health during the third quarter worth approximately $2,236,000. Finally, Russell Investments Group Ltd. increased its position in Radius Health by 50.6% during the third quarter. Russell Investments Group Ltd. now owns 18,916 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 6,354 shares during the period.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.